Neurorevix, an innovative medical device enterprise focused on brain‑computer interface (BCI) and neuromodulation technologies, announced the completion of an Angel round financing of tens of millions RMB. The round was led by HSG, with participation from Yuanming Brain Science Fund.
Contents
Financing Snapshot
| Item | Detail |
|---|---|
| Round | Angel |
| Size | Tens of millions RMB (exact amount not disclosed) |
| Announcement Date | 28 Sep 2026 |
| Lead Investor | HSG |
| Participating Investor | Yuanming Brain Science Fund |
| Company | Neurorevix – BCI and neuromodulation medical device developer |
| Use of Proceeds | Not disclosed; company is advancing its technology platform toward first‑in‑class product development and industrialization |
Company Profile & Technology Platform
- Sector Focus: Innovative medical devices in brain‑computer interface (BCI) and neuromodulation technologies.
- Core Platform: Built around its globally original “BCI + Precise Closed‑Loop Modulation of Nerve Bundles” technology platform.
- Full‑Stack In‑House R&D: Capabilities spanning three pillars –
- Flexible electrodes for high‑precision neural interfaces;
- Dedicated BCI chips purpose‑built for neural signal processing;
- Adaptive closed‑loop algorithms that modulate nerve bundles in real time based on neural feedback.
- Translation Strategy: Aims to translate platform technology from clinical needs into the development and industrialization of a series of global first‑in‑class products.
- Therapeutic Vision: Providing innovative therapeutic solutions for hundreds of millions of patients with neurological and psychiatric disorders worldwide, with the goal of reshaping the treatment paradigm for functional neural and psychiatric impairment.
Technology Context – Closed‑Loop Neuromodulation
- Open‑Loop vs. Closed‑Loop: Conventional neuromodulation delivers fixed stimulation regardless of a patient’s real‑time neural state; closed‑loop systems sense neural signals and adaptively titrate therapy, a design associated with improved precision and tolerability in neuromodulation.
- Nerve Bundle Targeting: Precise modulation at the level of nerve bundles – rather than diffuse stimulation – seeks to engage specific neural circuits implicated in functional neural and psychiatric impairment.
- BCI Convergence: The integration of BCI sensing with adaptive stimulation positions the platform at the frontier where brain‑machine interfacing meets implantable therapy, one of the most active areas of next‑generation neurotechnology.
Market Impact & Outlook
- Investor Validation: An Angel round led by HSG – one of Asia’s most prominent venture firms – signals early institutional conviction in Neurorevix’s differentiated “BCI + Precise Closed‑Loop Modulation of Nerve Bundles” approach amid intensifying global competition in neurotechnology.
- Market Opportunity: Neurological and psychiatric disorders affect hundreds of millions of patients worldwide, with large unmet need for device‑based therapies beyond pharmacology.
- Competitive Positioning: Full‑stack, in‑house development across electrodes, chips, and algorithms reduces reliance on external components and supports the company’s ambition of global first‑in‑class products.
- Execution Watch Items: Translation of platform technology into lead product candidates, preclinical and clinical development milestones, regulatory pathways for implantable neuromodulation devices, and industrialization timelines (not disclosed).
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Neurorevix’s technology platform development, product pipeline, clinical translation, regulatory pathways, and industrialization plans. Actual results may differ materially due to risks including development setbacks, regulatory requirements for implantable medical devices, competition, and financing conditions.-Fineline Info & Tech
